Consensus Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
4.98 ^USD	+18.85%		+11.16%	+101.62%

16/05	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise	MT
09/05	Transcript : Ventyx Biosciences, Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on Ventyx Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

53af883c8228fb6f74710a3171c.GlnGb5oYdVbNLkJeLZyX6y3xCx59b1ISbILXy4VfpAY.VDLyAfhUOiWkfxsxSsaivBSTSSgnVxojOeqQoOFu3DRwGpY9wyoTB693IQ~483f452b1f36e430870b3e7bcc3fe68c

Analyst Recommendations on Ventyx Biosciences, Inc.

Canaccord Genuity Trims Price Target on Ventyx Biosciences to $15 From $16, Maintains Buy Rating	13/03	MT
Oppenheimer Upgrades Ventyx Biosciences to Outperform From Perform, $12 Price Target	12/03	MT
Wells Fargo Upgrades Ventyx Biosciences to Overweight From Equal Weight, Raises Price Target to $16 From $7	12/03	MT
Canaccord Genuity Adjusts Ventyx Biosciences' Price Target to $16 From $20, Maintains Buy Rating	11/03	MT
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target	29/02	MT
Wells Fargo Cuts Ventyx Biosciences Price Target to $3 From $8, Maintains Equal Weight Rating	19/12	MT
Stifel Adjusts Price Target on Ventyx Biosciences to $2 From $6, Maintains Hold Rating	18/12	MT
HC Wainwright Downgrades Ventyx Biosciences to Neutral From Buy	07/11	MT
Stifel Downgrades Ventyx Biosciences to Hold From Buy, Cuts Price Target to $6 From $56	07/11	MT
Oppenheimer Downgrades Ventyx Biosciences to Perform From Outperform, Removes $56 Price Target	07/11	MT
Evercore ISI Lowers Ventyx Biosciences' Price Target to $47 From $65, Maintains Outperform Rating	10/23/10	MT
Oppenheimer Adjusts Ventyx Biosciences Price Target to $56 From $57, Maintains Outperform Rating	10/23/10	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	10/23/10	DJ
Morgan Stanley Adjusts Price Target on Ventyx Biosciences to $46 From $45, Maintains Overweight Rating	29/23/29	MT
Credit Suisse Adjusts Ventyx Biosciences' Price Target to $62 From $63, Keeps Outperform Rating	11/23/11	MT
Oppenheimer Adjusts Ventyx Biosciences Price Target to $57 From $62, Maintains Outperform Rating	11/23/11	MT
HC Wainwright Adjusts Price Target on Ventyx Biosciences to $52 From $54, Maintains Buy Rating	11/23/11	MT
HC Wainwright Raises Ventyx Biosciences' Price Target to $54 From $50, Buy Rating Kept	13/23/13	MT
Oppenheimer Adjusts Ventyx Biosciences Price Target to $62 From $65, Maintains Outperform Rating	24/23/24	MT
Wells Fargo Starts Ventyx Biosciences at Overweight With $77 Price Target	21/23/21	MT
Oppenheimer Adjusts Ventyx Biosciences Price Target to $65 Fro $60, Maintains Outperform Rating	20/23/20	MT
Canaccord Genuity Adjusts Ventyx Biosciences Price Target to $54 From $35, Maintains Buy Rating	31/23/31	MT
Oppenheimer Adjusts Ventyx Biosciences Price Target to $60 From $55, Maintains Outperform Rating	27/23/27	MT
Goldman Sachs Starts Ventyx Biosciences at Buy With $50 Price Target	19/22/19	MT
Morgan Stanley Initiates Ventyx Biosciences With Overweight Rating, Sets Price Target at $45	17/22/17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.98 USD

Average target price

10.7 USD

Spread / Average Target

+114.86%

High Price Target

21 USD

Spread / Highest target

+321.69%

Low Price Target

5 USD

Spread / Lowest Target

+0.40%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ventyx Biosciences, Inc.

Canaccord Genuity
Oppenheimer
Wells Fargo Securities
LifeSci Capital
Stifel Nicolaus
HC Wainwright
Evercore ISI
Morgan Stanley
Credit Suisse
Goldman Sachs
Piper Sandler
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar